Plain-English translation of NCT07692152 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a drug called , which works by helping your immune system fight cancer, can replace a traditional chemotherapy drug (mitomycin) in the standard treatment for anal squamous cell carcinoma. You would receive the new medication along with radiation therapy and another chemotherapy pill called . The trial wants to see if this approach is as effective at treating the cancer while potentially causing fewer serious side effects.
Mitomycin, the current standard chemotherapy drug used alongside radiation for anal cancer, can cause significant side effects. This medication represents a newer approach using immunotherapy, which might be equally or more effective while being easier to tolerate.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the standard treatment or the new treatment with . Both groups will undergo radiation therapy (IMRT) combined with chemotherapy pills and either mitomycin or administered during treatment. You will attend regular clinic visits for monitoring, blood tests, and imaging scans to assess how well the treatment is working and watch for any side effects. The study team will follow you closely for at least 6 months after radiation to evaluate your response to treatment.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China